• Pharmacists Center

    The Pharmacists Center features helpful resources, links, and tools supporting healthcare provider and patient education as well as useful information for practicing oncology pharmacists. Pharmacists Center

  • Nurses Center

    The Nurses Center features helpful resources, links, and tools supporting nurse and patient education as well as the practice of oncology nursing. Nurses Center

  • Fellows Center

    The Fellows Center features helpful resources, links, and tools supporting oncology fellows' education and current clinical practice. Fellows Center

References

  1. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420-430.

  2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.

  3. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther. 2005;4:139-163.

  4. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005;55:178-194.

  5. Bree RT, Stenson-Cox C, Grealy M, Byrnes L, Gorman AM, Samali A. Cellular longevity: role of apoptosis and replicative senescence. Biogerontology. 2002;3:195-206.

  6. Fulda S, Debatin KM. Apoptosis signaling in tumor therapy. Ann N Y Acad Sci. 2004;1028:150-156.

  7. Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med. 2005;258:479-517.

  8. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov. 2008;7:1001-1012.

  9. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421-3428.

  10. Garber K. New apoptosis drugs face critical test. Nat Biotechnol. 2005;23:409-411.

  11. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26:1324-1337.

  12. Häcker G, Weber A. BH3-only proteins trigger cytochrome c release, but how? Arch Biochem Biophys. 2007;462:150-155.

  13. Reed JC. Proapoptotic multidomain Bcl2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ. 2006;13:1378-1386.

  14. Shoemaker AR, Mitten MJ, Oleksijew A, et al. The Bcl-2 family inhibitor ABT-263 shows significant anti-tumor efficacy in models of B cell non-Hodgkin's lymphoma. Blood. 2006;108:A825.

  15. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005;5:876-885.

  16. Kischkel RC, Lawrence DA, Chuntharapai A, et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 2000;12:611-620.

  17. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 2008;26:3621-3630.